medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2017, Número 08

<< Anterior Siguiente >>

Ginecol Obstet Mex 2017; 85 (08)


Evidencias en indicaciones de la progesterona

Buitrón-García FR, Bailón-Uriza R, Santoyo-Haro S, Díaz-Sánchez V

Idioma: Español
Referencias bibliográficas: 41
Paginas: 489-497
Archivo PDF: 222.11 Kb.


RESUMEN

Antecedentes: la progesterona es una hormona esteroide con participación en la ovulación, implantación, embarazo y regulación de la función uterina durante el ciclo menstrual y de otros órganos, como la glándula mamaria. Por su mecanismo de acción, la progesterona está indicada en distintos padecimientos ginecológicos y obstétricos: síndrome premenstrual, amenaza de aborto, parto pretérmino, hemorragia uterina disfuncional y mastalgia relacionada con el ciclo menstrual.
Objetivo: evaluar la seguridad y eficacia de la progesterona en pacientes con: síndrome premenstrual, amenaza de aborto y de parto pretérmino, hemorragia uterina disfuncional, mastalgia y terapia hormonal en la menopausia.
Metodología: revisión sistemática de la evidencia científica acerca de las distintas indicaciones de la progesterona.
Resultados: se encontraron 92 artículos de los que se seleccionaron 41 para revisión.
Conclusiones: la evidencia clínica evaluada acerca de las indicaciones de la progesterona demuestra ventajas en eficacia y seguridad en los diferentes esquemas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Al-Asmakh. Reproductive functions of progesterone. Middle East Fertility Society 2007;12(3):147-152.

  2. Orizaba-Chávez B, Albo-Jasso G, Ocharán-Hernández M. Farmacocinética de la progesterona. Rev Hosp Jua Mex 2013; 80(1):59-66.

  3. Wieser F. Progesterone increases the number of Langerhans cells in human vaginal epithelium. Fertility and Sterility 2001;75(6):1234-1235.

  4. Marx S, Wentz M, MacKay L, et al. Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix. Journal of Histochemistry & Cytochemistry 2006;54(6):623-639.

  5. Bargallo M, Domínguez L, Licata G, et al. Vascular effects of progesterone. Role of celular calcium regulation. Hypertension 2001;37:142-147.

  6. Szmuilowiez E, Adler G, Williams J, et al. Relationship between Aldosterone and Progesterone in the human menstrual cycle. The Journal of Clinical Endocrinology & Metabolism 2006;91(10):3981-3987.

  7. Subhash C, Shashi K. Diagnosis and treatment of premenstrual dysphoric disorder. American Academy of Family Physicians 2002;66(7):1239-1248.

  8. Ford O, Lethaby A, Roberts H, Mol BWJ. Progesterone for premenstrual syndrome. Cochrane Database System Rev 2009;2:CD003415. DOI: 10.1002/14651858.CD003415. pub3.

  9. Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Progesterone Study Group. Br J Gen Pract 1995;45(400):589-93.

  10. Vanselow W, Dennerstein L, Greenwood KM. Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol 1996;17(1):29-38.

  11. Paragiano A, Bulleti C, Pace MC. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann N Y Acad Sci 2004;1034:200-210.

  12. Wahabi HA, Abed Althagafi NF, Elawad M. Progestogen for treating threatened miscarriage. Cochrane Database System Rev 2007;3:CD005943. DOI: 10.1002/14651858. CD005943.pub2.

  13. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database System Rev 2008;2: CD003511. DOI: 10.1002/14651858. CD003511.pub2.

  14. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database System Rev 2013;10:CD003511. DOI: 10.1002/14651858.CD003511.pub3.

  15. Conde-Agudelo, Romero R, Nicolaides K. Vaginal progesterone vs cervical cerclaje for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. Am J Obstet Ginecol 2013;208:42.e1-18.

  16. Di Renzo GC, Cabero Roura L, Facchinetti F. Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern-Fetal Neo M 2011;24(5):659-667.

  17. Roelens K, Robertfroid D, Ahmadzai N. Prevention of preterm birth in women at risk: select topics-Abstract. Good Clinical Practice (GPC); Brussels: Belgian Health Care Knowledge Centre (KCE). 2014. KCE Reports. D/2014/10.273/62

  18. Sánchez-Rodríguez O, Bello de Ita A. Parto pretérmino. Guía de práctica clínica. COMEGO 2015. 250-285.

  19. National Institute for Health and Care Excellence. Preterm labour and birth. NICE Guidelines 2015. 1-25 [Disponible en: https://www.nice.org.uk/guidance/NG25]

  20. Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004947. DOI: 10.1002/14651858. CD004947.pub2.

  21. Fonseca EB, Bittar RE, Carvalho MHB. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled doubleblind study. Am J Obstet Gynecol 2003;188:419-424.

  22. Fonseca EB, Celik E, Parra M. Progesterone and the risk of preterm birth among women with a short cérvix. NEJM 2007,357:462-9.

  23. Martinez de Tejada B, Karolinski A, Ocampo Mc, et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised doubleblind pacebo-controlled trial. BJOG 2015;122(1):80-91.

  24. American College of Obstetricians and Gynecologists. Use of progesterone to reduce preterm birth. Committee Opinion No. 419. Washington, DC: American College of Obstetricians and Gynecologists; 2008.

  25. McNahara HC, Wood R, Chalmers J, et al. STOPPIT Baby follow-up –Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One 2015:10(4):e0122341.

  26. Norman JE, Marlow N, Messow CM. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicenter, randomized, double-blind trial. The lancet 2016. Disponible en: http://dx.doi.org/10.1016/S0140- 6736(16)00350-0).

  27. Rosolowichi V, Saettller E, Szuck B. Mastalgia. Clinical Practice Guideline (Num. 170). SOGC 2006;49-57.

  28. Nappi, C, Affinito P, DiCarlo C, Esposito G. Montemagno U. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest 1992;15:801-6.

  29. Euhus DM, Uyehara C. Influence of parental progesterone’s on the prevalence and severity of mastalgia in pre-menopausal women: a multi-institutional cross-sectional study. J Am Coll Surg 1997;84:596-604.

  30. Mainero-Ratchelous FE, López-Valle MA, Iturralde- Rosas P. Mastalgia. Guía de Práctica Clínica COMEGO 2015;101-115.

  31. Stanczyk FZ, Hapgood JP, Winer S, Mishell D. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions and clinical effects. Endocrine Rev 2013; 34: 171-208.

  32. Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485-490.

  33. L’Hermite M, Simoncine T, Fuller S, et al. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185-201.

  34. Khul H. Pharmacology of Progestogens. J Reproduktionsmed Endokrinol 2011;8(Special Issue 1):157-76.

  35. Vademecum PR [actualizado 2014]. Disponible en: http:// mx.prvademecum.com/producto.php?producto=2594

  36. The Royal Australian and New Zealand College of Obstetricians and Gynecologist (RANZCOG). Menopausal Hormone Therapy Advice. Australia: RANZCOG;2015.

  37. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2012;19(3):257-271.

  38. The Society of Obstetricians and gynaecologist of Canada. (SOGC) Abnormal uterine bleeding in pre-menopausal women. 2013;FIGO, 2011.

  39. Derman SG, Rehnstrom J, Neuwirth RS. The long term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991;77:591-594.

  40. Alanís-Fuentes J, Zacarías-Castillo R. Sangrado uterino anormal (y el endocrinólogo). Endocrinol Nutr 2005;13(1):39-46.

  41. Stacy R.A., Nelson A.L. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot sudy. Am J Obstet Gynecol 2013;208:499.e1-5.




2020     |     www.medigraphic.com